IMDX vs NTRA
IMDX: iMDx is disrupting the transplant diagnostics market by enabling hospitals to run their own donor-derived cell-free DNA (dd-cfDNA) tests in-house through a decentralized kitted model. NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications.
Side-by-side fundamentals
| Metric | IMDX | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $3.03 | $405.92 | |
| Market cap | $99M | $58.5B | |
| Net margin FY2025, SEC XBRL | -1238.5% | -9.0% | NTRA higher |
| Gross margin FY2025, SEC XBRL | +56.7% | n/a | |
| Operating margin FY2025, SEC XBRL | -1260.8% | -13.4% | NTRA higher |
| ROE FY2025, SEC XBRL | n/a | -12.2% | |
| ROA FY2025, SEC XBRL | -195.0% | -8.7% | NTRA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.04 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +115.6% | +35.9% | IMDX higher |
| Revenue CAGR (3y) SEC XBRL | +61.8% | +41.1% | IMDX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.91 | 1.29 | |
| 1-year return as of 2026-10-20 close | -48.6% | +115.2% | NTRA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.